First-quarter 2026 Rezdiffra® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127%As of March 31, 2026, more than ...

Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead PharmaceuticalsPrecision approach ...

First-quarter 2026 Rezdiffra- (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127%As of March 31, 2026, more than 42,250 patients on Rezdiffra, up 2.5x from 1Q25, refle ...

Madrigal Pharmaceuticals reported strong first-quarter revenue growth driven by Rezdiffra adoption while expanding its MASH ...

Cybersecurity is more important than ever, as cybercrime losses surpassed $20 billion in 2025, according to the Federal Bureau of Investigation (FBI), a roughly 25% increase from 2024. Credit ...

All three drugmakers have proven fairly innovative in their respective niches. Clinical and commercial progress could send their share prices soaring. Kystal Biotech focuses on developing medicines ...

Cardiac issues are just one reason you might have telemetry monitoring. You might need it after surgery, recovery from a stroke, or if you have blood clots.(Photo Credit: E+/Getty Images.) Telemetry ...

Rezdiffra (resmetirom) is a brand-name drug prescribed for a type of liver disease called metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH) ...

We independently evaluate all of our recommendations. If you click on links we provide, we may receive compensation. Brendan is a full-time senior editor of financial products and services at ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

You’ve likely spent most of your adult life building good credit. Now, imagine you can’t qualify for financing because your credit score has suddenly dropped, thanks to an identity thief who opened ...

At the 2025 EASL Congress, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) presented promising two-year data from its Phase 3 MAESTRO-NAFLD-1 trial, showing Rezdiffra significantly reduced liver ...